Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2–Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2–Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial
1. 系统已在2025-04-07 12:17:18对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1200/JCO.23.02044
文献链接: https://ascopubs.org/doi/10.1200/JCO.23.02044
其他信息:
出版社: American Society of Clinical Oncology (ASCO)
作者: Herui Yao; Min Yan; Zhongsheng Tong; Xinhong Wu; Min-Hee Ryu; John J. Park; Jee Hyun Kim; Yahua Zhong; Yiming Zhao; Mark Voskoboynik; Yongmei Yin; Kan Liu; Andreas Kaubisch; Caigang Liu; Jian Zhang; Shouman Wang; Seock-Ah Im; Vinod Ganju; Minal Barve; Hui Li; Changsheng Ye; Amitesh C. Roy; Li-Yuan Bai; Chia-Jui Yen; Shanzhi Gu; Yung-Chang Lin; Lingying Wu; Lequn Bao; Kaijing Zhao; Yu Shen; Shangyi Rong; Xiaoyu Zhu; Erwei Song
